Difelikefalin-d5 (hydrochloride)

Difelikefalin-d5 (CR-845-d5) hydrochloride is the deuterium labeled Difelikefalin (HY-17609) . Difelikefalin (CR-845) is a peripherally restricted and selective agonist of kappa opioid receptor (KOR) . Difelikefalin produces anti-inflammatory effects and has the potential in modulating pruritus in conditions such as chronic kidney disease[1][2].

Product Specifications

Product Name Alternative

CR-845-d5 (hydrochloride) ; FE-202845-d5 (hydrochloride)

UNSPSC

12352005

Target

Isotope-Labeled Compounds; Opioid Receptor

Related Pathways

GPCR/G Protein; Neuronal Signaling; Others

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Purity

97.58

Smiles

O=C(C1(N)CCN(C([C@@H](CCCCN)NC([C@@H](CC(C)C)NC([C@@H](CC2=CC=CC=C2)NC([C@@H](CC3=C([2H])C([2H])=C([2H])C([2H])=C3[2H])N)=O)=O)=O)=O)CC1)O.Cl.Cl.Cl

Molecular Formula

C36H51D5Cl3N7O6

Molecular Weight

794.26

References & Citations

[1]Steven Fishbane, et al. Randomized Controlled Trial of Difelikefalin for Chronic Pruritus in Hemodialysis Patients. Kidney Int Rep. 2020 Jan 28;5 (5) :600-610.|[2]Steven Fishbane, et al. A Phase 3 Trial of Difelikefalin in Hemodialysis Patients With Pruritus. N Engl J Med. 2020 Jan 16;382 (3) :222-232.